Engineered TREM2 antibody clears Aβ in mice

Microglia migrate towards and phagocytose amyloid-β (Aβ), both in its oligomeric form and in plaques. The microglial receptor TREM2 has a crucial role in this process, and new data indicate that a TREM2 agnostic antibody can accelerate the removal of amyloid. Weekly administration of the antibody to 5×FAD mice — a model of Alzheimer disease — was associated with reduced Aβ burden, greater phagocytosis of Aβ plaques by microglia and improved cognitive function. The findings highlight the promise of engineering TREM2 antibodies to treat Alzheimer disease, but further work is needed before this approach is used in the clinic.

留言 (0)

沒有登入
gif